2020
Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis
D’Amico G, Abraldes JG, Rebora P, Valsecchi MG, Garcia‐Tsao G. Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis. Hepatology 2020, 72: 1029-1042. PMID: 31837238, PMCID: PMC11090179, DOI: 10.1002/hep.31070.Peer-Reviewed Original ResearchConceptsClinical trialsGrade 1Prevention of decompensationBaseline platelet countDevelopment of varicesSignificant outcome differencesLow baseline riskPrimary therapeutic targetCirrhosis decompensationCompensated cirrhosisInception cohortComposite endpointEsophageal varicesPlatelet countBinary outcomesDisease progressionSignificant treatment effectBaseline riskGrade 3Sample sizeOutcome differencesTherapeutic targetDecompensationGrade 2Larger sample size
2019
Outcomes After Listing for Liver Transplant in Patients With Acute‐on‐Chronic Liver Failure: The Multicenter North American Consortium for the Study of End‐Stage Liver Disease Experience
O’Leary J, Bajaj JS, Tandon P, Biggins SW, Wong F, Kamath PS, Garcia‐Tsao G, Maliakkal B, Lai J, Fallon M, Vargas HE, Thuluvath P, Subramanian R, Thacker LR, Reddy K. Outcomes After Listing for Liver Transplant in Patients With Acute‐on‐Chronic Liver Failure: The Multicenter North American Consortium for the Study of End‐Stage Liver Disease Experience. Liver Transplantation 2019, 25: 571-579. PMID: 30724010, PMCID: PMC11075742, DOI: 10.1002/lt.25426.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAcute-On-Chronic Liver FailureAdultDisease ProgressionEnd Stage Liver DiseaseFemaleHospital MortalityHospitalizationHumansLiver CirrhosisLiver TransplantationMaleMiddle AgedNorth AmericaProspective StudiesRenal DialysisSeverity of Illness IndexSurvival RateTime-to-TreatmentWaiting ListsConceptsChronic liver failureLiver transplantationNorth American ConsortiumLiver failureEnd-stage liver disease (MELD) scoreEnd-stage liver diseaseAmerican ConsortiumExtrahepatic organ failureAcute kidney injuryLiver Disease scoreOutcomes of patientsPost-LT survivalPerioperative dialysisRenal recoveryKidney injuryLiver transplantOrgan failureLiver diseaseMedian timeMedian MELDACLFSimilar survivalDisease experienceDisease scorePatients
2012
Association of AKI With mortality and complications in hospitalized patients with cirrhosis
Belcher JM, Garcia‐Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, Coca SG, Parikh CR, Consortium F. Association of AKI With mortality and complications in hospitalized patients with cirrhosis. Hepatology 2012, 57: 753-762. PMID: 22454364, PMCID: PMC3390443, DOI: 10.1002/hep.25735.Peer-Reviewed Original ResearchConceptsAcute kidney injuryAcute Kidney Injury Network definitionAssociation of AKIDefinition of AKISeverity of AKIProgression of AKIProspective observational cohort studyAKIN stage 1Baseline renal functionObservational cohort studyIncidence of mortalityAKI criteriaAKI severityAKI stageAKIN criteriaAKIN stageHospital mortalityKidney injuryCohort studyDevastating complicationRenal functionHospitalized patientsImproved outcomesEarly diagnosisTimely treatment
2011
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis
Berzigotti A, Garcia‐Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, Escorsell A, Garcia‐Pagan J, Patch D, Matloff DS, Groszmann RJ, Group T. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011, 54: 555-561. PMID: 21567436, PMCID: PMC3144991, DOI: 10.1002/hep.24418.Peer-Reviewed Original ResearchMeSH KeywordsBody Mass IndexDisease ProgressionFemaleHumansLiver CirrhosisMaleMiddle AgedObesityRisk FactorsConceptsBody mass indexClinical decompensationPortal pressureBMI groupsNormal body mass indexRole of obesityChronic viral hepatitisIndependent risk factorSubset of patientsValuable therapeutic measureActuarial probabilityCompensated cirrhosisViral hepatitisAggressive courseIndependent predictorsMass indexRandomized trialsLiver functionPatient populationRisk factorsTherapeutic measuresStudy populationCirrhosisTreatment groupsPatients
2008
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay
Mayo MJ, Parkes J, Adams‐Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB, Saldana S, Getachew Y, Butsch R, Luketic V, Peters M, Di Bisceglie A, Bass N, Lake J, Boyer T, Martinez E, Boyer J, Garcia‐Tsao G, Barnes D, Rosenberg WM. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008, 48: 1549-1557. PMID: 18846542, PMCID: PMC2597274, DOI: 10.1002/hep.22517.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisSerum fibrosis markersBiliary cirrhosisLiver biopsyClinical progressionFibrosis markersLiver fibrosisPrognostic informationPrognostic performanceSerial liver biopsy specimensEnd-stage liver diseaseLong-term prognostic informationLiver-related deathPositive antimitochondrial antibodyMayo risk scoreEvent-free survivalAppropriate clinical settingSerum hyaluronic acidEnhanced liver fibrosisLiver biopsy specimensAccurate noninvasive measureFibrosis algorithmsPBC subjectsVariceal bleedBiopsy complications